Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes

References

• Centers for Disease Control and Prevention National Diabetes Fact Sheet: General information and national estimates on diabetes in the United States, 2007 Atlanta, GA US Department of Health and Human Services, Centers for Disease Control and Prevention 2008
   Google Scholar
• World Health Organization Diabetes fact sheet 312 11 2009 Available at: http://www.who.int/mediacentre/factsheets/fs312/en/print.html Accessed 2010 Sep 19
   Google Scholar
• Stratton IM Adler AI Neil HA Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 2000 321 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Ong KL Cheung BMY Wong LYF Prevalence, treatment and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999–2004 Ann Epidemiol 2008 18 222 229 18201902
   PubMed Web of Science ®Google Scholar
• Nathan DM Holman RR Buse JB Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Turner RC Cull CA Frighi V Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49) JAMA 1999 281 2005 2012 10359389
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 1999 131 281 303 10454950
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Oral antihyperglycemic therapy for type 2 diabetes JAMA 2002 287 360 372 11790216
   PubMed Web of Science ®Google Scholar
• Charpentier G Oral combination therapy for type 2 diabetes Diabetes Metab Res Rev 2002 18 S70 S76 12324989
   PubMed Web of Science ®Google Scholar
• Riddle MC Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations Endocrinol Metab Clin North Am 2005 34 77 98 15752923
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists Medical guidelines for clinical practice for the management of diabetes mellitus Endocr Pract 2007 13 S1 3 68
   Google Scholar
• Drucker DJ Nauck MA The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 1696 1706 17098089
   PubMed Web of Science ®Google Scholar
• Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 2003 26 2929 2940 14514604
   PubMed Web of Science ®Google Scholar
• Holst JJ Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1 Diabetes Metab Res Rev 2002 18 430 441 12469357
   PubMed Web of Science ®Google Scholar
• Aronoff SL Berkowitz K Shreiner B Glucose metabolism and regulation: Beyond insulin and glucagon Diabetes Spectr 2004 17 183 190
   Google Scholar
• Ahren B Dipeptidyl peptidase-4 inhibitors Diabetes Care 2007 30 1344 1350 17337494
   PubMed Web of Science ®Google Scholar
• Herman GA Stevens C van Dyck K Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 2005 78 675 688 16338283
   PubMed Web of Science ®Google Scholar
• Herman GA Stein PP Thornberry NA Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin Clin Pharmacol Ther 2007 81 761 767 17392725
   PubMed Web of Science ®Google Scholar
• Merck and Co, Inc. 2010 Januvia prescribing information Available at: http://www.januvia.com/sitagliptin/januvia/hcp/januvia/about_januvia/prescribing_information.jsp Accessed 2010 Jun 3
   Google Scholar
• Goodarzi MO Bryer-Ash M Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents Diabetes Obes Metab 2005 7 654 665 16219009
   PubMed Web of Science ®Google Scholar
• Bailey CJ Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones Diabetes Obes Metab 2005 7 675 691 16219011
   PubMed Web of Science ®Google Scholar
• Mannucci E Ognibene A Cremasco F Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects Diabetes Care 2001 24 489 494 11289473
   PubMed Web of Science ®Google Scholar
• Lenhard JM Croom DK Minnick DT Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments Biochem Biophys Res Comm 2004 324 92 97 15464987
   PubMed Web of Science ®Google Scholar
• Scheen AJ Clinical pharmacokinetics of metformin Clin Pharmacokinet 1996 30 359 371 8743335
   PubMed Web of Science ®Google Scholar
• Salpeter S Greyber E Pasternak G Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 2006 1 CD002967 16437448
   PubMedGoogle Scholar
• Herrington WG Levy JB Metformin: Effective and safe in renal disease? Int Urol Nephrol 2008 40 411 417 18368503
   PubMed Web of Science ®Google Scholar
• Migoya E Miller J Larson P A randomized, placebo-controlled, double-blind, double-dummy, crossover study to assess the effects of sitagliptin and metformin on post-meal incretin hormone concentrations in healthy adult subjects Oral presentation OR-0286 at the 67th meeting of the American Diabetic Association 2007 Jun 22–26 Chicago, IL
   Google Scholar
• Charbonnel B Karasik A Liu J Wu M Meininger G Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone Diabetes Care 2006 29 2638 2643 17130197
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Johnson J Teng R Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: A 54-week study Curr Med Res Opin 2009 25 569 583 19232032
   PubMed Web of Science ®Google Scholar
• Raz I Chen Y Wu M Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr Med Res Opin 2008 24 537 550 18194595
   PubMed Web of Science ®Google Scholar
• Nauck MA Meininger G Sheng D Fanurik D Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double blind, non-inferiority trial Diabetes Obes Metab 2007 9 194 205 17300595
   PubMed Web of Science ®Google Scholar
• Scott R Loeys T Davies MJ Engel SS Sitagliptin Study 801 Group Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 2008 10 959 969 18201203
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Okerson T Viswanathan P Guan X Holcombe JH MacConell L Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study Curr Med Res Opin 2008 24 2943 2952 18786299
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck M Bailey T 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26 week, randomized, parallel-group, open-label trial Lancet 2010 375 1447 1456 20417856
   PubMed Web of Science ®Google Scholar
• Monami M Iacomelli I Marchionni N Mannucci E Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 2010 20 224 235 19515542
   PubMed Web of Science ®Google Scholar
• Richter B Bandeira-Echtler E Bergerhoff K Lerch C Dipeptidyl peptidase-4(DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2008 16 CD006739 18425967
   PubMedGoogle Scholar
• FDA post-marketing drug safety information Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed 2009 Sep 19
   Google Scholar
• Dore DD Seeger JD Arnold Chan K Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared with metformin or glyburide Curr Med Res Opin 2009 25 1019 1027 19278373
   PubMed Web of Science ®Google Scholar
• Goodarzi MO Bryer-Ash M Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents Diabetes Obes Metab 2005 7 654 665 16219009
   PubMed Web of Science ®Google Scholar
• Moretto TJ Milton DR Ridge TD Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2008 30 1448 1460 18803987
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Bethel MA Green JB Califf RM Holman RR Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS) Diabetologia 2009 52 S1 S480
   Google Scholar
• Williams-Herman D Engel SS Round E Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord 2010 10 7 20412573
   PubMed Web of Science ®Google Scholar